Federal Criminal Statutes. Experts discuss the Court’s refusal to read statutes broadly and the importance of judges considering the impacts of race and addiction in sentencing.
Joseph LaFratta, Mary Page Kelley, Jason A. Cantone
December 3, 2020
Chief Magistrate Judge M. Page Kelley (D. Mass.) and Deputy Chief Probation Officer Joseph LaFratta (D. Mass.) discuss the structure, commitment required, and lessons learned from their court’s experience with a successful drug treatment court program.
Dr. Christopher Jones, U.S. Public Health Service and Centers for Disease Control and Prevention (CDC), reviews current options (to include methadone, buprenorphine and naltrexone) in Medication-Assisted Treatment (MAT) for those with an opioid use disorder.
Dr. Kelly Dunn, from the Johns Hopkins University School of Medicine, explains how psychologists treat individuals with opioid use disorder and chronic pain, which includes techniques such as cognitive behavioral therapy (CBT).
Dr. Wilson Compton, deputy director of the National Institute on Drug Abuse (NIDA), explains what judges need to know about the biology, neurobiology, and chemistry of opioid use disorder.
Dr. Robert Redfield, director of the Centers for Disease Control and Prevention (CDC), identifies drug use disorder as the public health crisis of our time.
Judge Irene M. Keeley (N.D. W. Va.) introduces this series, designed to provide judges with a basic understanding of opioid use and its effect on the federal courts, and outlines the objective: to equip judges with a series of takeaways they can readily apply in their respective courts.
Chief Justice Loretta Rush (Indiana Supreme Court) shares her experience as a chair of the National Judicial Opioid Task Force, presenting the findings of the task force as well as new resources and a call for enhanced cooperation between federal and state courts in addressing the opioid crisis.